|1.||Pantopoulos, Kostas: 1 article (03/2012)|
|2.||Koromilas, Antonis E: 1 article (03/2012)|
|3.||Daba, Alina: 1 article (03/2012)|
|4.||Eizenbach, Menahem: 1 article (11/2005)|
|5.||Friedrich, Inbar: 1 article (11/2005)|
|6.||Levitzki, Alexander: 1 article (11/2005)|
|7.||Sajman, Julia: 1 article (11/2005)|
|8.||Ben-Bassat, Hannah: 1 article (11/2005)|
|9.||Kamau, Edwin: 1 article (09/2004)|
|10.||Grove, Anne: 1 article (09/2004)|
01/01/1986 - "The results indicate that coumermycin is potent against MRSA with activity equal or superior to comparable agents in various experimental mouse infections."
11/01/2005 - "This "PKR killing screen" is based on the infection of cells with an adenoviral vector encoding GyrB-PKR, followed by coumermycin treatment. "
08/01/1984 - "The effect of coumermycin A1 activity on the infection and replication of murine type C retroviruses was studied in vitro. "
01/01/1986 - "Coumermycin was active in a local thigh infection while vancomycin was inactive. "
01/01/1986 - "Coumermycin retained activity when given 18 h before an MRSA infection, while vancomycin activity was lost. "
04/01/1987 - "aureus strains isolated from the blood of patients with endocarditis were tested in vitro against coumermycin with precautions to avoid carry-over of the antibiotic. "
04/01/1987 - "Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination."
12/01/1991 - "The observation that gyrase B subunit inhibitors antagonised the bactericidal activity of 4-quinolones is in accordance with the report previously made by others that ciprofloxacin combined with coumermycin was less effective than ciprofloxacin alone in treating staphylococcal endocarditis in rats. "
04/01/1987 - "The efficacy of a 5-day treatment with coumermycin A1 (hereafter referred to as coumermycin) (at three dosage regimens), with ciprofloxacin, or with coumermycin plus ciprofloxacin was tested in experimental aortic valve endocarditis induced in rats by a strain of methicillin-susceptible Staphylococcus aureus and was compared with the efficacy of a 5-day treatment with cloxacillin plus gentamicin. "
01/01/2004 - "Novobiocin, a coumermycin antibiotic, is known to enhance anticancer drug sensitivity of cancer cells in vitro and in vivo, the mechanism of which remains undetermined. "
01/01/1990 - "The coumermycin antibiotic novobiocin is currently under investigation as an agent that can modify the toxicity of various anti-cancer drugs, potentially via one of its many pharmacological effects: namely, the interference with type II DNA topoisomerase function. "
|4.||Lyme Disease (Disease, Lyme)
10/01/1994 - "The coumermycin A1-resistant gyrB marker and genetic transformation can now be applied toward dissecting the physiology and pathogenesis of the Lyme disease agent on a molecular genetic level."
01/01/1993 - "Furthermore, structural analogs of coumermycin may be considered as treatments for Lyme disease."
01/01/1993 - "Coumermycin A1 inhibits growth and induces relaxation of supercoiled plasmids in Borrelia burgdorferi, the Lyme disease agent."
|9.||DNA (Deoxyribonucleic Acid)
|10.||Type II DNA Topoisomerases (Topoisomerase II)